

CLAIMS

What is claimed is:

1. A bispecific antibody that binds TRAIL receptor 1 and TRAIL receptor 2.
2. A bispecific antibody of claim 1, wherein the antibody is a monoclonal antibody.
3. A bispecific antibody of claim 1, wherein the antibody induces death in a target cell selected from the group consisting of a cancer cell and a virally-infected cell.
4. A bispecific antibody of claim 2, wherein the antibody induces death in a target cell selected from the group consisting of a cancer cell and a virally-infected cell.
5. A bispecific antibody of claim 3, wherein the target cell is a virally-infected cell.
6. A bispecific antibody of claim 4, wherein the target cell is a virally-infected cell.
7. A bispecific antibody of claim 3, wherein the target cell is a cancer cell.
8. A bispecific antibody of claim 4, wherein the target cell is a cancer cell.
9. A bispecific antibody of claim 7, wherein the cancer cell is selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
10. A bispecific antibody of claim 8, wherein the cancer cell is selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
11. A method for killing cancer cells, comprising contacting cancer cells with a bispecific antibody of claim 7.
12. A method of claim 11, wherein the cancer cells are selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
13. A method for killing cancer cells, comprising contacting cancer cells with a bispecific antibody of claim 8.

14. A method of claim 13, wherein the cancer cells are selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
15. A method of claim 13, wherein the antibody comprises at least one Fc region.
16. A method of claim 13, wherein the antibody is a whole antibody.
17. A method for killing virally infected cells, comprising contacting virally infected cells with a bispecific antibody of claim 5.
18. A method for killing virally infected cells, comprising contacting virally infected cells with a bispecific antibody of claim 6.
19. A method of claim 17, wherein the cells are infected with human immunodeficiency virus (HIV).
20. A method of claim 18, wherein the cells are infected with human immunodeficiency virus (HIV).
21. A method of claim 18, wherein the antibody comprises at least one Fc region.
22. A method of claim 18, wherein the antibody is a whole antibody.
23. A method for killing cancer cells *in vivo*, comprising administering a bispecific antibody of claim 7 to a human who has cancer.
24. A method of claim 23, wherein the cancer cells are selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
25. A method for killing cancer cells *in vivo*, comprising administering a bispecific antibody of claim 8 to a human who has cancer.

26. A method of claim 25, wherein the cancer cells are selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
27. A method of claim 25, wherein the antibody comprises at least one Fc region.
28. A method of claim 25, wherein the antibody is a whole antibody.
29. A method of claim 23, wherein the antibody is co-administered with one or more additional anti-cancer agents.
30. A method for killing virally infected cells *in vivo*, comprising administering a bispecific antibody of claim 5 to a human who is infected with a virus.
31. A method for killing virally infected cells *in vivo*, comprising administering a bispecific antibody of claim 6 to a human who is infected with a virus.
32. A method of claim 30, wherein the virus is human immunodeficiency virus.
33. A method of claim 31, wherein the virus is human immunodeficiency virus.
34. A method of claim 31, wherein the antibody comprises at least one Fc region.
35. A method of claim 31, wherein the antibody is a whole antibody.
36. A method of claim 30, wherein the antibody is co-administered with one or more additional anti-viral agents.